Lexium International is one of the world's largest non-prescription pharmaceutical companies producing next generation pharmaceuticals for doctors, hospitals & pharmacies as well as non-prescription outlets in 47 countries. Lexium International applies the science of perfecting and improving current medications and OTC formulations to produce “non-prescription pharmaceutical alternatives” without the side effects. In other words, we keep all the effective attributes of an effective medication and remove many or all of the negative side effects. Lexium International invests heavily in unique delivery systems, advanced formulations, cancer research and drug development. The Company is the largest corporate investor in the bio-tech cancer drug development company Kalos Therapeutics The products are manufactured in the US and UK and distributed and sold in 47 countries.